BI-1206 ke moemeli ea ka sehloohong oa lithethefatsi oa BioInvent 'me hajoale e ntse e fuputsoa litekong tse peli tsa Mokhahlelo oa 1/2. E 'ngoe ke ho hlahloba motsoako oa BI-1206 le rituximab bakeng sa phekolo ea Non-Hodgkin lymphoma, e kenyeletsang bakuli ba FL, MCL le marginal zone lymphoma (MZL) ba khutletseng morao kapa ba hanang ho rituximab. Teko ea Mokhahlelo oa bobeli oa 1/2 e etsa lipatlisiso ka BI-1206 hammoho le anti-PD1 therapy Keytruda® (pembrolizumab) ka har'a lihlahala tse tiileng.
Ngaka Wei-Wu He, Molula-setulo le CEO oa CASI o ile a fana ka maikutlo a hore, "BioInvent e ntse e tsoela pele ka nts'etsopele le moralo oa taolo oa BI-1206. Tumello ea CTA naheng ea China ka Tšitoe 2021 le lebitso la morao-rao la FDA Orphan Drug Designation li bonts'a bokhoni bo matla ba antibody ena ea boemo ba pele. CASI e na le litokelo tsa khoebo tsa China tsa BI-1026, 'me sehlopha sa rona se itokisetsa boithuto ba bongaka ba China. CASI le BioInvent ke balekane ba se nang moeli 'me ba na le sepheo se le seng sa ho thusa bakuli ba nang le mahlale a macha a meriana.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- One is evaluating the BI-1206 combination with rituximab for the treatment of Non-Hodgkin lymphoma, which includes patients with FL, MCL and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab.
- The CTA approval in China in December 2021 and the recent FDA Orphan Drug Designation demonstrate the strong potential of this first-in-class antibody.
- A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
